# Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

> **NCT01188252** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 112 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Roniciclib (BAY1000394)

## Key facts

- **NCT ID:** NCT01188252
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188252, "Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01188252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*